RFA-PS-24-042: A Bridge to Adherence: Long-Acting Antiretroviral Therapy for People with HIV Released from Prison
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2023.
Centers for Disease Control and Prevention - ERA offered grants of up to $375,000 (at least $285,000) to nonprofits, colleges and universities, state and local governments, tribes and businesses. It expected to make about 2 awards worth $3.0 million in total. Applications closed on March 1, 2024.
From the official notice on Grants.gov, last changed December 1, 2023. Checked November 7, 2026.
- Award ceiling$375,000
- Award floor$285,000
- Total funding$3.0 million
- Expected awards2
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | December 1, 2023 |
|---|---|
| Deadline | March 1, 2024 |
| Archived by Grants.gov | March 31, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes and businesses.
All 14 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
N/A
Is this a realistic fit?
- Past Prevention of Disease, Disability, and Death by Infectious Diseases awards averaged $1.9 million; this notice allows up to $375,000 per award.
- No cost sharing or match is required.
What the grant funds
Each year, approximately 6,500 persons with HIV living in prison facilities are released to the community, often lacking support for ongoing HIV care. There is a paucity of programming for this population that demonstrates effective retention in HIV care and sustained HIV viral suppression after release. The use of long-acting injectable antiretroviral therapy (LAI-ART) prior to and at the time of release from prison may improve adherence to HIV treatment, retention in care, and maintenance of viral load suppression among persons reentering the community. The primary purpose of this Notice of Funding Opportunity (NOFO) is to support the development and implementation of effective, sustainable, replicable LAI-ART programs for prison facilities and to understand the feasibility and acceptability of providing LAI-ART to persons with HIV living in prisons who are to be released to the community. Applied qualitative and quantitative research resulting from this funding is expected to strengthen adherence to ART.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before
From fiscal 2021 to 2025, Prevention of Disease, Disability, and Death by Infectious Diseases (93.084) awarded $241 million across 128 grant awards, an average of $1.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Puerto Rico Science, Technology, and Research Trust | Puerto Rico | 4 | $14.5 million |
| Massachusetts Department of Public Health | Massachusetts | 1 | $11.6 million |
| Emory University | Georgia | 3 | $11.5 million |
| Uganda Virus Research Institute | 1 | $8.7 million | |
| Ponce Medical School Foundation Inc | Puerto Rico | 2 | $8.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-PS-24-042 still open?
No. It closed on March 1, 2024. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for A Bridge to Adherence: Long-Acting Antiretroviral Therapy for People with HIV Released from Prison?
Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for A Bridge to Adherence: Long-Acting Antiretroviral Therapy for People with HIV Released from Prison?
Closed March 1, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $375,000 each. About $3.0 million in total across about 2 awards.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before?
The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)